- Home
- PHIO vs OSRH Comparison
PHIO vs OSRH Comparison
Compare PHIO & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- OSRH
- Stock Information
- Founded
- PHIO 2011
- OSRH N/A
- Country
- PHIO United States
- OSRH United States
- Employees
- PHIO N/A
- OSRH N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- OSRH
- Sector
- PHIO Health Care
- OSRH
- Exchange
- PHIO Nasdaq
- OSRH Nasdaq
- Market Cap
- PHIO 12.1M
- OSRH 13.2M
- IPO Year
- PHIO N/A
- OSRH N/A
- Fundamental
- Price
- PHIO $2.16
- OSRH $0.74
- Analyst Decision
- PHIO Strong Buy
- OSRH
- Analyst Count
- PHIO 3
- OSRH 0
- Target Price
- PHIO $10.67
- OSRH N/A
- AVG Volume (30 Days)
- PHIO 70.7K
- OSRH 2.0M
- Earning Date
- PHIO 11-13-2025
- OSRH 11-24-2025
- Dividend Yield
- PHIO N/A
- OSRH N/A
- EPS Growth
- PHIO N/A
- OSRH N/A
- EPS
- PHIO N/A
- OSRH N/A
- Revenue
- PHIO N/A
- OSRH $104,735.00
- Revenue This Year
- PHIO N/A
- OSRH N/A
- Revenue Next Year
- PHIO N/A
- OSRH N/A
- P/E Ratio
- PHIO N/A
- OSRH N/A
- Revenue Growth
- PHIO N/A
- OSRH N/A
- 52 Week Low
- PHIO $0.97
- OSRH $0.45
- 52 Week High
- PHIO $9.79
- OSRH $13.40
- Technical
- Relative Strength Index (RSI)
- PHIO 47.27
- OSRH 58.79
- Support Level
- PHIO $2.08
- OSRH $0.59
- Resistance Level
- PHIO $2.17
- OSRH $0.91
- Average True Range (ATR)
- PHIO 0.10
- OSRH 0.11
- MACD
- PHIO -0.01
- OSRH 0.02
- Stochastic Oscillator
- PHIO 25.64
- OSRH 59.35
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.